Envisioning a New Cancer Diagnostic and Therapeutic Platform

On the Road to 50 States, Frances Johnson and Mike Schultz of Viewpoint Molecular Targeting, Inc. talk to Nigel about how the company's novel approach to cancer treatment will help patients across the world.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Viewpoint Molecular Targeting, Inc.

Viewpoint Molecular Targeting® is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. Viewpoint’s leading lead-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that utilize the same targeting peptide for the purpose of personalizing treatment and optimizing patient outcomes. This theranostic  approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.